Last reviewed · How we verify
Temozolamide, irinotecan
At a glance
| Generic name | Temozolamide, irinotecan |
|---|---|
| Also known as | CPT-11, Campto, Irinotecan, Temozolamide |
| Sponsor | Grupo Español de Investigación en Neurooncología |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors (PHASE1)
- Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy (PHASE3)
- Metronomic Temozolamide in Patients With Recurrent Glioblastoma (PHASE2, PHASE3)
- Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Temozolamide, irinotecan CI brief — competitive landscape report
- Temozolamide, irinotecan updates RSS · CI watch RSS
- Grupo Español de Investigación en Neurooncología portfolio CI